Baxter and 5 More Medical Device Stocks Primed to Bounce Back

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 41 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 20%
  • Publisher: 97%

Deutschland Nachrichten Nachrichten

Deutschland Neuesten Nachrichten,Deutschland Schlagzeilen

Some investors have worried that new weight-loss drugs could undermine demand for some medical devices.

The share prices of medical device companies have been circling the drain this year, as worries over the impact of the new obesity medicines weigh on the stocks.

Since the summer, investors have grown increasingly worried that the new weight-loss drugs from Eli Lilly and Novo Nordisk will bring on vast changes in Americans’ health, which could undermine demand for many of the products sold by medical device companies. Such fears have led to “$370 billion total market cap destruction across U.S. MedTech,” Petrone wrote.

“It remains to be seen, it’s early days,” Wolk said of the obesity drugs’ impact on his company’s medtech business.To identify medical device stocks with room to grow, we screened the iShares U.S. Medical Devices ETF for companies with market values over $5 billion and with average analyst target prices implying the largest potential upside. The idea was to find the medical device stocks that analysts have the most faith in.

Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

 /  🏆 3. in DE
 

Vielen Dank für Ihren Kommentar.Ihr Kommentar wird nach Prüfung veröffentlicht.

Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

MedTech Earnings in the Age of Ozempic May Not Be That BadSeptember-quarter earnings among medical-device makers may prove better than expected in the age of weight-loss drugs.
Herkunft: MarketWatch - 🏆 3. / 97 Weiterlesen »